CYP1B1-RMDN2 Alzheimer’s disease endophenotype locus identified for cerebral tau PET
Open Access
- 20 September 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Abstract
Determining the genetic architecture of Alzheimer’s disease pathologies can enhance mechanistic understanding and inform precision medicine strategies. Here, we perform a genome-wide association study of cortical tau quantified by positron emission tomography in 3046 participants from 12 independent studies. The CYP1B1-RMDN2 locus is associated with tau deposition. The most significant signal is at rs2113389, explaining 4.3% of the variation in cortical tau, while APOE4 rs429358 accounts for 3.6%. rs2113389 is associated with higher tau and faster cognitive decline. Additive effects, but no interactions, are observed between rs2113389 and diagnosis, APOE4, and amyloid beta positivity. CYP1B1 expression is upregulated in AD. rs2113389 is associated with higher CYP1B1 expression and methylation levels. Mouse model studies provide additional functional evidence for a relationship between CYP1B1 and tau deposition but not amyloid beta. These results provide insight into the genetic basis of cerebral tau deposition and support novel pathways for therapeutic development in AD.Keywords
Funding Information
- Foundation for the National Institutes of Health (R01 AG019771, P30 AG072976, U19 AG024904, R01 AG057739, R01-AG061796, U19-AG074879)
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01-NS080820)
- Alzheimer's Association (Alzheimer’s Association Zenith Fellows Award)
This publication has 88 references indexed in Scilit:
- Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairmentNeurology, 2007
- Principal components analysis corrects for stratification in genome-wide association studiesNature Genetics, 2006
- Age-Dependent Neurofibrillary Tangle Formation, Neuron Loss, and Memory Impairment in a Mouse Model of Human Tauopathy (P301L)The Journal of Neuroscience, 2005
- Tau Suppression in a Neurodegenerative Mouse Model Improves Memory FunctionScience, 2005
- Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun NH2-terminal kinase activation induced by arsenic.2003
- Elevated hepatic and depressed renal cytochrome P450 activity in the Tg2576 transgenic mouse model of Alzheimer's diseaseJournal of Neurochemistry, 2002
- Induction of NADPH cytochrome P450 reductase by the Alzheimer β‐protein. Amyloid as a ‘foreign body’Journal of Neurochemistry, 2001
- High-Level Neuronal Expression of Aβ1–42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque FormationThe Journal of Neuroscience, 2000
- The Role of Oxidative Stress in Alzheimer DiseaseArchives of Neurology, 1999
- Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse modelsProceedings of the National Academy of Sciences, 1999